Syncona Creates Second Gene Therapy Company With £25m Financing
This article was originally published in Scrip
The Wellcome Trust's investment subsidiary Syncona LLP has put £25m of series A financing into a new gene therapy company, Freeline Therapeutics, spun off from University College London (UCL) via its technology transfer arm UCL Business PLC. Freeline's initial focus will be on bleeding disorders.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.